ST. PAUL, Minn.--(BUSINESS WIRE)--June 16, 2006--St. Jude Medical, Inc. (NYSE:STJ - News) today announced the clinical trial results, receipt of European CE Mark approval and European market launch of its QuickOpt(TM) Timing Cycle Optimization. The trial results were presented by James G. Porterfield, M.D., principal investigator in the trial conducted under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE), during a late-breaking clinical trial session at Cardiostim 2006 in Nice, France.
